November 12, 2024 Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024 read more
November 5, 2024 Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024 read more
October 28, 2024 New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information read more
CTAD 2024 Quanterix Fireside Chat with Henrik Zetterburg: Advances in Blood-Based Biomarkers for Alzheimer’s Disease read more
May 17, 2024 Q&A: Blood-based biomarker testing ‘scientific consensus favorite’ for AD detection read more
January 26, 2024 Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer’s Disease Pathology read more
October 3, 2023 Ultrasensitive immunoassay technology drives blood-based biomarkers for Alzheimer’s disease read more
December 2, 2024 CTAD 2024 Fuels the Momentum in Advancing Alzheimer’s Disease Detection & Treatment with a Spotlight on Blood-Based Biomarkers read more
October 3, 2024 Insights from ECTRIMS 2024: Exploring MS Biomarkers and the Role of Quanterix read more